Patents
US 11674139 B2: Oligonucleotides for treating expanded repeat diseases
- Granted
- 2023-06-13
- Filed
- 2018-07-18 application 16038580
- Type
- Utility · 18 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
The invention provides for a method for selectively reducing the expression of a mutant mRNA and/or protein having an expanded nucleotide repeat relative to a wild-type mRNA, comprising contacting a cell with an antisense oligonucleotide of sufficient length and complementarity to the expanded nucleotide repeat. More particularly it relates to selectively reducing the expression of mutant Huntington protein associated with Huntington's disease. The antisense oligonucleotide comprising either a nucleotide or a repeated three nucleotide sequence as defined in the claims.
Source: PVGPATDIS, file of 2026-04-10 (ipg230613.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| SAREPTA THERAPEUTICS, INC. 126 patents | US company or organization | Cambridge, MA | Sarepta Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state SAREPTA THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally | PVGPATDIS, file of 2026-04-10 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Peter S. Linsley | Seattle, WA | 24 | PVGPATDIS, file of 2026-04-10 | |
| Brian James Leppert | Kenmore, WA | 4 | PVGPATDIS, file of 2026-04-10 | |
| Gunnar J. Hanson | Cambridge, MA | 58 | PVGPATDIS, file of 2026-04-10 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C12N | Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media | C12N15/113 | PVGPATDIS, file of 2026-04-10 |
| A61P | Specific therapeutic activity of chemical compounds or medicinal preparations | A61P21/02 | PVGPATDIS, file of 2026-04-10 |
| C07F | Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium | C07F9/65583 | PVGPATDIS, file of 2026-04-10 |
| C07H | Sugars; derivatives thereof; nucleosides; nucleotides; nucleic acids | C07H21/04 | PVGPATDIS, file of 2026-04-10 |
| C12Q | Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | C12Q1/6883 | PVGPATDIS, file of 2026-04-10 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2025-05-07 | Security interest Security interest Security interest | SAREPTA THERAPEUTICS, INC. signed 2025-02-13 | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT CHICAGO, IL | 71218/445 | PASDL, file of 2026-10-15 |
| 2019-02-19 | Assignment Assignment of assignor's interest | LINSLEY, PETER signed 2012-11-27 LEPPERT, BRIAN JAMES signed 2012-10-04 HANSON, GUNNAR J. signed 2012-11-13 | SAREPTA THERAPEUTICS, INC. BOTHEL, WA | 48372/238 | PASDL, file of 2026-10-15 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.